Get the Stockscreener App
12.94
3.31%
0.415
Generate Biomedicines Inc stock is traded at $12.94, with a volume of 729.53K.
It is up +3.31% in the last 24 hours and down -20.11% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$12.52
Open:
$12.53
24h Volume:
729.53K
Relative Volume:
0.63
Market Cap:
$1.66B
Revenue:
Net Income/Loss:
P/E Ratio:
-6.0012
EPS:
-2.1554
Net Cash Flow:
1W Performance:
-7.54%
1M Performance:
-20.11%
6M Performance:
+3.48%
1Y Performance:
+0.00%
1-Day Range:
$12.43
$13.08
1-Week Range:
$12.10
$14.86
52-Week Range:
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
888-469-0055
Address
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
12.94 | 1.66B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | H.C. Wainwright | Buy |
| Mar-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-24-26 | Initiated | Goldman | Buy |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Mar-24-26 | Initiated | Morgan Stanley | Overweight |
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
View All
Generate Biomedicines Inc Stock (GENB) Latest News
An ovarian cancer trial tests cell therapy without chemotherapy beforehand. Its first patient has been dosed. - Stock Titan
Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions - Simply Wall Street
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines (NasdaqGS:GENB) Stock Price - Simply Wall Street
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P Global BMI Index - marketscreener.com
Generate Biomedicines (GENB) Slips 3.15% as Shares Test Support Near $15Max Pain Level - dars.gov.et
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com South Africa
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com India
Generate Biomedicines (GENB) Slips 3% as Shares Test Key Support at $15.11Imbalance Zone - dars.gov.et
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Generate Biomedicines Inc. to Participate in September Investor Conferences - marketscreener.com
Five September talks will stream online from Generate Biomedicines - Stock Titan
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
102,450,201 Common Stock of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
8 Stocks Nvidia Has Invested InU.S. News - U.S. News - Money
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Generate Biomedicines Shares Fall Following Q2 Financial Results - Yahoo Finance
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines: Q2 Earnings Snapshot - AOL.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines (GENB) Slips 4.4% to $13.85 as Biotech Uncertainty Weighs on SharesModified Schiff - vinanet.vn
Generate Biomedicines Inc Stock (GENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generate Biomedicines Inc Stock (GENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ARNOLD FRANCES | Director |
Sep 01 '26 |
Proposed Sale |
16.00 |
1,000 |
16,002 |
0 |
| Nally Michael | Chief Executive Officer |
Mar 04 '26 |
Buy |
12.00 |
20,000 |
240,000 |
572,707 |
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
2.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):